Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6641164 | 0.95 | CTDSP1 (0.34) | HTR6CTDSP1 | |
| SCHEMBL735596 | 0.95 | CTDSP1 (0.34) | HTR6CTDSP1 | |
| SCHEMBL2007704 | 0.93 | CTDSP1 (0.33) | HTR6CTDSP1 | |
| SCHEMBL737622 | 0.93 | CTDSP1 (0.33) | HTR6CTDSP1 | |
| SCHEMBL735469 | 0.92 | CTDSP1 (0.31) | CTDSP1 | |
| SCHEMBL175373 | 0.92 | — | — | |
| SCHEMBL738719 | 0.90 | CTDSP1 (0.34) | CTDSP1 | |
| SCHEMBL2009169 | 0.90 | SLC18A3 (0.31) | CTDSP1 | |
| SCHEMBL14343220 | 0.90 | — | — | |
| SCHEMBL736119 | 0.90 | SLC18A3 (0.31) | CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43390-E1 | Pleuromutilin derivatives as antimicrobials | GLAXOSMITHKLINE LLC (US) | 2012-05-15 | — | — | US | claimed |
| EP-1930330-B1 | Pleuromutilin derivatives as antimicrobials | SMITHKLINE BEECHAM LTD (GB) | 2011-09-21 | — | — | EP | claimed |
| US-7820680-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2010-10-26 | — | — | US | claimed |
| EP-1725102-A4 | HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1930330-A1 | Pleuromutilin derivatives as antimicrobials | SMITHKLINE BEECHAM PLC (GB) | 2008-06-11 | — | — | EP | claimed |
| US-20080009490-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | claimed |
| EP-1725102-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | claimed |
| US-20060166341-A1 | Method for reproducing pleuromutilins | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | claimed |
| US-7074929-B2 | Certain alkylene diamine-substituted heterocycles | NEUROGEN CORP. (US) | 2006-07-11 | — | — | US | claimed |
| US-RE39128-E1 | ANTIBACTERIA DRUG; RESPIRATORY SYSTEM DISORDERS; OTITIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-06-13 | — | — | US | claimed |
| US-6372743-B1 | EATING DISORDERS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | NEUROGEN CORPORATION | 2002-04-16 | — | — | US | claimed |
| US-6281226-B1 | Pleuromutilin derivatives as antimicrobials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-28 | — | — | US | claimed |
| WO-2001023389-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | claimed |
| WO-2001023387-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | claimed |
| WO-2001005758-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS ALLELIX CORP. (CA) | 2001-01-25 | — | — | WO | claimed |
| US-6121281-A | Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-09-19 | — | — | US | claimed |
| EP-1028961-A1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-23 | — | — | EP | claimed |
| EP-0934316-A1 | AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 1999-08-11 | — | — | EP | claimed |
| WO-1999021855-A1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-05-06 | — | — | WO | claimed |
| WO-1998005659-A1 | AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 1998-02-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009490-A1 | Hiv Integrase Inhibitors | TYMS, UNG, TYMP | HTR6 4512/4885CTDSP1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.